Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Public ClinicalTrials.gov record NCT07080242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Study identification
- NCT ID
- NCT07080242
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 120 participants
Conditions and interventions
Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced
- Neuroendocrine Cancer
- Metastatic Neuroendocrine Prostate Cancer
- Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Metastatic Advanced Merkel Cell Carcinoma
- Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung
- Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
- Locally Advanced Neuroendocrine Prostate Cancer
- Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine
- Locally Advanced Merkel Cell Carcinoma
- Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2025 (Actual)
- Primary completion
- Dec 31, 2027 (Estimated)
- Completion
- Dec 31, 2027 (Estimated)
- Last update posted
- Sep 16, 2026
2025 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | Not yet recruiting |
| Los Alamitos Hematology/Oncology Medical Group | Glendale | California | 91203 | Recruiting |
| MemorialCare Long Beach Medical Center | Long Beach | California | 90806 | Recruiting |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | Recruiting |
| UCLA | Los Angeles | California | 90095 | Not yet recruiting |
| UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center) | San Francisco | California | 94158 | Not yet recruiting |
| University of Colorado - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520-8028 | Recruiting |
| Emory Winship | Atlanta | Georgia | 30322 | Recruiting |
| Tulane School of Medicine | New Orleans | Louisiana | 70112 | Recruiting |
| START - New Jersey | East Brunswick | New Jersey | 08816 | Recruiting |
| John Theurer Cancer Center-Hackensack | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Recruiting |
| Ohio State University | Columbus | Ohio | 43201 | Recruiting |
| Providence Cancer Institute | Portland | Oregon | 97213 | Recruiting |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | Recruiting |
| NEXT Dallas | Dallas | Texas | 75039 | Recruiting |
| START Dallas- Fort Worth | Dallas | Texas | 76104 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| NEXT Houston | Houston | Texas | 77054 | Recruiting |
| START- San Antonio | San Antonio | Texas | 78229 | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
| University of Washington/Fred Hutchinson Cancer Center | Seattle | Washington | 98195 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07080242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07080242 live on ClinicalTrials.gov.